SCHEDULE: Innovation Endeavors Discloses 6.2% Stake in Eikon
Schedule 13G
Investment firm Innovation Endeavors has reported a 6.2% beneficial ownership stake in Eikon Therapeutics, Inc. as of March 31, 2026.
Summary
- Innovation Endeavors III LP, IV LP, and ET SPV LP collectively hold 3,369,519 shares of Eikon Therapeutics, Inc. common stock.
- This aggregate holding represents 6.2% of the company's total outstanding common stock.
- The filing confirms shared voting and investment authority among the various Innovation Endeavors entities and their respective general partners.
- The reporting entities expressly disclaim status as a group for the purposes of this Schedule 13G filing.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure indicating institutional interest without signaling immediate strategic shifts.
Positives
- Demonstrates institutional investor confidence in Eikon Therapeutics' long-term prospects.
- Provides transparency regarding significant shareholding positions.
Negatives
- None identified in this regulatory disclosure.
Risks
- Concentration of voting power among affiliated investment entities.
- Market volatility associated with biotech sector investments.
Future Outlook
The filing does not provide forward-looking guidance regarding the issuer's business operations or the investors' future trading intentions.
Industry Context
StockSavvy.ai notes that this filing is a standard regulatory disclosure for institutional investors crossing the 5% ownership threshold, common in the venture capital-backed biotechnology sector.
Comparison to Industry Standards
- The filing adheres to standard SEC requirements for Schedule 13G disclosures.
- The reporting structure is consistent with typical venture capital fund management practices.
Stakeholder Impact
- Provides clarity to existing shareholders regarding the concentration of ownership.
Next Steps
- The reporting persons will continue to monitor their investment in Eikon Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 2026-03-17 | Date used for total shares outstanding calculation. |
| 2026-03-30 | Date of Eikon Therapeutics' Annual Report on Form 10-K. |
| 2026-03-31 | Date of event requiring the filing of this statement. |
| 2026-05-15 | Date of the Schedule 13G filing. |
Keywords
Eikon Therapeutics, Innovation Endeavors, Schedule 13G, Institutional Ownership, Biotech Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.